Evidence map›Paper›PMID 40002291›Full record

ArticleCancers2025

Prognostic Value of Pretreatment

Daniela Travaglio Morales, Mónica Coronado Poggio, Carlos Huerga Cabrerizo, Itsaso Losantos García, Cristina Escabias Del Pozo, Carmen Lancha Hernández, Sonia Rodado Marina, Luis Domínguez Gadea

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela Travaglio MoralesNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.
Mónica Coronado PoggioNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.
Carlos Huerga CabrerizoLa Paz University Hospital, 28046 Madrid, Spain.
Itsaso Losantos GarcíaBiostatistics Department, La Paz University Hospital, 28046 Madrid, Spain.
Cristina Escabias Del PozoNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.
Carmen Lancha HernándezNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.
Sonia Rodado MarinaNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.
Luis Domínguez GadeaNuclear Medicine Department, La Paz University Hospital, 28046 Madrid, Spain.ORCID 0000-0002-0778-4755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the prognostic value of pretreatment

methodsA review of 47 patients diagnosed with advanced HGSOC between 2012 and 2020 in our center was performed, evaluating pretreatment

resultsThe median DFS was 18 months (2.5-55) and the OS 33.6 months (2.5-92). The MTVtotal, MTV(t), TLGtotal and TLG(t) were significantly associated with DFS (

conclusionsPretreatment MTVtotal and MTV(t) appear to be predictive of relapse in patients with advanced HGSOC.

Indexed as

metabolic parametersovarian cancerPET/CTprognosis

Identifiers

PMID40002291
PMCPMC11853401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.